TrialArthritis and rheumatism2010

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Joan T Merrill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.